Skip to main content

Table 2 prognostic factors of distant progression free survival and overall survival

From: Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer

 PFSOS
UnivariateMultivariateUnivariateMultivariate
HRIC95ppHRIC95pp
PET-TDM  0.59 0.44[0.20,0.94]0.068 
Oligometastatic site  0.136   0.020.37
Indication (oligometastatic spectrum) (ref = oligometastases)  0.040.029  0.030.02
Center  0.498   0.477 
Age (ref= > 63 y)0.69[0.43,1.12]0.134 0.42[0.23,0.76]0.0040.003
Gender (ref = male)0.89[0.55,1.46]0.65 1.11[0.62,1.98]0.731 
Smoking habits0.66[0.34,1.26]0.226 1.25[0.53,2.95]0.593 
Comorbidities0.999[0.61,1.65]0.992 1.42[0.78,2.57]0.223 
Free interval (ref > 516 days)2.41[1.28,4.51]0.001 3.23[1.37,7.61]0.002 
Primary cancer controlled1.24[0.63,2.44]0.498 1.14[0.48,2.70]0.77 
Number of metastatic lesions =2 (ref = 1)1.18[0.53,2.60]0.695 0.962[0.38,2.43]0.928 
Number of previous systemic treatment lines  0.777   0.133 
Synchronous lesion (ref = metachronous)0.90[0.53,1.54]0.716 1.09[0.60,1.99]0.779 
Histology  0.985   0.685 
EGFR mutation or ALK translocation1.56[0.77,3.15]0.252 0.83[0.37,1.85]0.581 
Initial T stage (ref = T1)
 T21.3[0.66,2.58]0.2 1.79[0.73,4.4]0.020.008
 T30.8[0.39,1.75] 0.79[0.29,2.2]
 T41.9[0.84,4.5] 3[1.05,8.4]
Initial N+ status (ref = N0)1.71[1.01,2.90]0.0350.0221.29[0.69,2.425]0.411 
  1. Boldface entries = statistically significant